Effect of thyrotropin suppressive therapy on heart rate variability and QT dispersion in patients with differentiated thyroid cancer. Issue 28 (10th July 2020)

• Record Type: Journal Article
• Authors: Liu, Chunhua; Lv, Haihong; Li, Qian; Fu, Songbo; Tan, Jiaojiao; Wang, Chenyi; Wang, Xiaoqian; Ma, Yuping
• Other Names: Barzilay. Joshua section editor.
• Is Part Of: Medicine. Volume 99:Issue 28(2020)
• Publication Date: 2020-07-10
• Subjects: Differentiated thyroid cancer -- TSH suppressive therapy -- Heart rate variability -- QT dispersion; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000021190
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: The effects of thyrotropin (TSH) suppressive therapy on autonomic regulation and ventricular repolarization in patients with differentiated thyroid cancer (DTC) have not been elucidated. The aim of present study was to evaluate variation in heart rate variability (HRV) and QT dispersion after TSH suppressive therapy in patients with DTC. Cases, defined as 271 patients with DTC within 1 year of exogenous levothyroxine, and all patients underwent a full history, physical examination, including standard 12 lead electrocardiogram (ECG), and 24 h ambulatory ECG monitoring (Holter) with normal free thyroxine (FT4) and free triiodothyronine (FT3) with levothyroxine. To evaluate effects of TSH suppressive therapy on HRV and QT dispersion, patients were divided into three groups according to different levels of TSH: TSH < 0.1 mIU/L group and 0.1 ⩽ TSH < 0.5 mIU/L group were as TSH suppression groups, and 0.5 ⩽ TSH < 2.0 mIU/L group was as TSH replacement group. Comparing with 0.5 ⩽ TSH < 2.0 mIU/L group, significant changes in both time and frequency domain of HRV and QT dispersion were observed in TSH < 0.1 mIU/L group ( P < .001: SDNN, SDANN, HF, LF/HF, QTd, and QTcd; P < .05: rMSSD) and 0.1 ⩽ TSH < 0.5 mIU/L group ( P < .001: SDNN, HF, LF/HF, QTd, and QTcd), and especially were more pronounced in TSH < 0.1 mIU/L group. Moreover, we found that TSH level was proportional to SDNN (β = 15.829, P < .001), but inversely proportional to LF/HF (β = −0.671, P < .001), QTd (β = −16.674, P < .001) and QTcd (β = −18.314, P < .001) in DTC patients with exogenous levothyroxine. Compared with euthyroid state, patients with suppressed serum TSH have increased sympathetic activity in the presence of diminished vagal tone, ultimately showed sympathovagal imbalance and with an increased inhomogeneity of ventricular recovery times. These findings revealed that TSH suppression therapy had a significant impact on cardiovascular system and had certain guiding role in the treatment and management of patients with DTC.